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ABSTRACT
Purpose: Splenic hilar lymph node dissection (LND) during total gastrectomy is regarded 
as the standard treatment for proximal advanced gastric cancer (AGC). This study aimed 
to investigate whether splenic hilar LND or D2 LND is essential for proximal AGC of pT2-
4aN0M0 stage.
Materials and Methods: Data of curative total gastrectomies (n=370) performed from 
2000 to 2010 for proximal AGC of pT2-4aN0 stage were retrospectively reviewed. 
Clinicopathological characteristics and long-term outcomes were compared using propensity 
score matching between patients who underwent splenectomy (n=43) and those who did not 
(n=327) and between patients who underwent D2 LND (n=122) and those who underwent 
D1+ LND (n=248).
Results: Tumors of larger size and a more advanced T stage and significantly lower overall 
and relapse-free survival (P<0.001) were observed in the splenectomy group than in the 2 
spleen-preserving groups. Before propensity score matching, worse overall and relapse-free 
survival (P<0.001) was observed in the splenectomy group than in the non-splenectomy 
group. After matching, although the overall survival became similar (P=0.123), relapse-free 
survival was worse in the splenectomy group (P=0.021). Compared with D1+ LND, D2 LND 
had no positive impact on the overall (P=0.619) and relapse-free survival (P=0.112) after 
propensity score matching.
Conclusions: Splenic hilar LND with or without splenectomy may not have an oncological 
benefit for patients with pathological AGC with no LN metastasis.
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INTRODUCTION
In cancer treatment, adequate surgical resection, including lymph node dissection (LND), 
is essential to achieve a curative state. In advanced gastric cancer (AGC), total or subtotal 
gastrectomy with D2 LND is widely performed as the standard treatment [1-3]. Since 
proximal gastric cancer, which has a steadily rising incidence [4], metastasizes to the splenic 
hilar lymph nodes (LNs; station No. 10) in 9%–26% [5-8], D2 LND, including splenic hilar 
LND, is recommended for proximal AGC as per previous treatment guidelines [9].
To remove splenic hilar LNs, surgeons should perform splenectomy or spleen-preserving 
hilar LND. The theoretical background for the removal of splenic hilar LNs in AGC has 
been explored using lymphangiography [10]. With evidence of lymphatic flow from the 
upper greater curvature through the splenic hilum to the celiac trunk, splenectomy has 
been considered as an effective method for performing en-bloc resection of gastric cancer 
and adjacent LNs [10]. However, because of compromised immunological functions along 
with high morbidity and mortality rates, splenectomy poses serious adverse effects [11-13]. 
Meanwhile, because surgical techniques have improved, some experienced surgeons perform 
spleen-preserving hilar LND, which could be an ideal method [14,15]. Nevertheless, although 
this procedure is theoretically rational, it is technically challenging, and the oncological 
validity of the procedure remains unclear [14]. Thus, splenectomy and spleen-preserving 
hilar dissection should be avoided, if possible, because of the difficulty in the procedure and 
other aspects.
In previous Japanese guidelines, the decision of performing hilar LND was based on clinical 
T classification of cancer (T2 or more advanced lesion). However, the recently revised 
guidelines do not include splenic hilar LND for all proximal advanced cancers unless it 
involves the greater curvature of the stomach. However, even among the indicated patients, 
there may be patients who would gain little benefit or even detrimental effects from hilar 
dissection. Identifying the characteristics of this group of patients could be useful to prevent 
unnecessary hilar dissection.
In the present study, we presumed that pT2-4aN0 patients would not gain any additional 
oncological benefits from hilar dissection. Accordingly, we aimed to determine the survival 
impact of splenectomy or splenic hilar dissection in the proximal AGC patients without LN 
metastasis who underwent curative total gastrectomy. We also sought to investigate whether 
D2 LND, including splenectomy and spleen-preserving hilar dissection, should be mandatory 
for LN negative proximal AGC.
MATERIALS AND METHODS
Patients
By retrospectively analyzing our prospectively collected database from the Department 
of Surgery, Yonsei University College of Medicine from 2000 to 2010, we identified 2,453 
patients who underwent total gastrectomy for gastric cancer. Of these, 2,083 patients 
were excluded (87 patients were diagnosed with other malignancies before the operation 
and 92 patients were treated with preoperative chemotherapy or radiotherapy). A total of 
231 patients underwent non-curative surgery, among whom 120 had peritoneal seeding; 
81 had positive washing cytology or other organ metastasis, including para-aortic LN 
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metastasis; and 30 were not treated with R0 resection. Among the remaining patients, 
400 met the pathological T2-4aN0 criteria, among whom 30 patients having incomplete 
clinicopathological information were excluded. Finally, 370 patients were included in the 
analysis (Fig. 1). The clinicopathological characteristics (age, sex, histological differentiation, 
tumor location, gross type, size, and T classification) of the 370 patients were analyzed. 
This retrospective study was approved by the Institutional Review Board (IRB) of Severance 
Hospital Yonsei University College of Medicine (4-2017-0711). Because of the retrospective 
nature of the study, signed patient informed consent was waived as per the IRB approval.
Operation
Curative total gastrectomy with LND was performed following the Japanese Gastric Cancer 
Association (JGCA) classification guidelines [9]. A total of 370 patients underwent total 
gastrectomy with LND by open, laparoscopic, or robot-assisted methods for gastric cancer. 
The patients who met the indications of minimally invasive surgery at our institution were 
able to select the surgical procedure after receiving information on the advantages and 
disadvantages of each procedure.
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n=370
Unknown information
(n=30)
Fig. 1. Study profile.
Survival impact of splenectomy on node negative T2-4a gastric cancer patients
For the current study, we divided the patients into 3 groups: splenectomy group, spleen-
preserving hilar LND group (SPHLD group), and a group of patients in whom the extent 
of LND was not up to D2 dissection (D1+). To verify the survival impact of splenectomy on 
patients with proximal AGC, the splenectomy group was compared with the other 2 non-
splenectomy groups (SPHLND+D1+) in terms of clinicopathological characteristics and long-
term survival. Because the surgical treatment method or extent was pre-determined based 
on clinicopathological characteristics, we expected the study groups to show significant 
differences in perioperative outcomes, which we corrected using propensity score matching 
analysis. Accordingly, the long-term outcomes were compared by assessing overall and 
relapse-free survival among the groups before and after propensity score matching.
Survival impact of D2 LND on node negative T2-4a gastric cancer patients
In addition, the splenectomy plus SPHLD groups, which underwent D2 LND, were compared 
with the D1+ group to verify the oncological impact of D2 LND on node-negative T2-4a 
gastric cancer patients. In the same way, the clinicopathological characteristics and long-
term outcomes were analyzed for the D2 group and compared with the D1+ group.
Statistical analyses
The clinicopathological and long-term oncological results, including overall and relapse-free 
survival, were analyzed using the R package survival and Matchit (version 3.3.1). To minimize 
selection bias, seven perioperative variables representative of patient features (age and sex) 
and tumor characteristics (histological type, location, gross type, size, and T classification) 
were selected and matched 1:1 using propensity score matching, as these variables are 
considered to have a significant impact on patient survival. The patients were followed 
from the date of operation until December 31, 2014, or their death. Overall survival was 
defined from the date of operation to the last follow-up or death from any cause. Relapse-
free survival was defined from the date of operation to recurrence of gastric cancer or death 
from any cause. The patients were censored at the last follow-up if they did not experience 
the designated events. The overall and relapse-free survival were assessed using the Kaplan-
Meier method, and the differences in survival curves among the groups were examined 
using the log-rank test. The categorical and continuous variables were analyzed by the χ2 or 
Fisher's exact and Student's t-test, respectively. All P-values <0.05 (2-sided) were considered 
statistically significant. Multivariate analyses to assess the risk factors for overall survival 
were performed using the Cox proportional hazard model. The following variables were 
included in the analyses: age, sex, location, differentiation, Borrmann type, tumor size, and 
type of operation.
RESULTS
Demographic characteristics of the patients among the different groups and 
comparison of long-term survival
Among the 370 patients who underwent total gastrectomy for pT2-4aN0 proximal AGC, 43 
patients underwent splenectomy, and 79 patients underwent spleen-preserving hilar LND. 
The remaining 248 patients underwent surgery with limited LND, excluding station No. 10. 
The splenectomy group tended to have more advanced disease (Table 1). In the comparison 
of survival curves among the splenectomy, SPHLD, and D1+ groups, the splenectomy group 
had worse overall survival than the other 2 groups (P<0.001 for D1+, P=0.003 for SPHLD). 
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Relapse-free survival was also worse in the splenectomy group than the other two groups 
(P<0.001 for D1+, P=0.003 for SPHLD). There were no differences in the overall and relapse-
free survival between the SPHLD and D1+ groups (P=0.239 and P=0.061, respectively; Fig. 2).
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Table 1. Demographics of patients in the splenectomy, SPHLD, and D1+ groups
Characteristics Splenectomy (n=43) SPHLND (n=79) D1+ (n=248)
Mean age (yr) 56.1±13.7 55.5±12.5 55.1±12.5
Sex
Male 28 (65.1) 58 (73.4) 168 (67.7)
Female 15 (34.9) 21 (26.6) 80 (32.3)
Histologic type
Differentiated 11 (25.6) 24 (30.4) 88 (35.5)
Undifferentiated 32 (74.4) 51 (69.6) 160 (64.5)
Location
LC 21 (48.8) 28 (35.4) 108 (43.5)
GC 6 (14.0) 5 (6.3) 25 (10.1)
AW 2 (4.7) 16 (20.3) 47 (19.0)
PW 13 (30.2) 29 (36.7) 66 (26.6)
Circular 1 (2.3) 1 (1.3) 2 (0.8)
Gross type
Borrmann I 3 (7.0) 10 (12.7) 17 (6.9)
Borrmann II 11 (25.6) 21 (26.6) 62 (25.0)
Borrmann III 24 (55.8) 40 (50.6) 138 (55.6)
Borrmann IV 5 (11.6) 8 (10.1) 31 (12.5)
Mean tumor size (mm) 60.6±32.4 60.2±35.8 43.5±24.3
T classification
T2 8 (18.6) 22 (27.8) 100 (40.3)
T3 6 (14.0) 35 (44.3) 69 (27.8)
T4a 29 (67.4) 22 (27.8) 79 (31.9)
Data are shown as a mean±standard deviation or number of patients (proportion).
SPHLD = spleen-preserving hilar lymph node dissection; LN = lymph node; LC = lesser curvature; GC = greater 
curvature; AW = anterior wall; PW = posterior wall.
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Fig. 2. Kaplan-Meier overall and relapse-free survival curves for patients with splenectomy, SPHLD, and D1+ groups. (A) Overall survival among the 3 groups.  
(B) R-free survival among the 3 groups. 
SPHLD = spleen-preserving hilar lymph node dissection.
Comparison of the characteristics before and after propensity score 
matching between the splenectomy and non-splenectomy groups
To investigate the impact of splenectomy on pT2-4aN0 patients, the two non-splenectomy 
groups were combined and compared with the splenectomy group (splenectomy group 
[n=43] vs. non-splenectomy group [n=327, SPHLD+D1+]) (Table 2). In this comparison, 
a few clinicopathological characteristics were found to be significantly different between 
the 2 groups: The mean tumor size of the splenectomy group was 60.6 mm, whereas that 
in the non-splenectomy group was 44.0 mm (P<0.001). Furthermore, compared with the 
non-splenectomy group, the splenectomy group had an advanced T classification (P<0.001). 
After 1:1 propensity score matching for seven variables, 39 pairs of patients with similar 
clinicopathological characteristics, including age, sex, histological type, location, gross type, 
size, and T classification, were matched (P>0.05).
Comparison of long-term outcomes between the splenectomy and  
non-splenectomy groups
Comparing the survival curves, worse overall and relapse-free survival were observed in 
the splenectomy group (n=43) than in the non-splenectomy group (n=327) (P<0.001 and 
P<0.001, respectively) (Fig. 3A and B). After propensity score matching, a comparison 
of 39 matched pairs showed similar overall survival but worse relapse-free survival in the 
splenectomy group (P=0.123 and P=0.021, respectively) compared with those in the non-
splenectomy group (Fig. 3C and D).
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Table 2. Demographics of patients before and after propensity score matching between the splenectomy and non-splenectomy (SPHLD+D1+) groups
Characteristics Before matching After matching
Splenectomy (n=43) Non-splenectomy (n=327) P-value Splenectomy (n=39) Non-splenectomy (n=39) P-value
Mean age (yr) 56.1±13.7 55.5±12.4 0.769 56.7±14.0 58.9±12.0 0.456
Sex 0.595 1.000
Male 28 (65.1) 226 (69.1) 26 (66.7) 26 (66.7)
Female 15 (34.9) 101 (30.9) 13 (33.3) 13 (33.3)
Histologic type 0.257 0.792
Differentiated 11 (25.6) 112 (34.3) 10 (25.6) 9 (23.1)
Undifferentiated 32 (74.4) 215 (65.7) 29 (74.4) 30 (76.9)
Location 0.070 0.969
LC 21 (48.8) 136 (41.6) 19 (48.7) 20 (51.3)
GC 6 (14.0) 30 (9.2) 6 (15.4) 4 (10.3)
AW 2 (4.7) 63 (19.3) 2 (5.1) 2 (5.1)
PW 13 (30.2) 95 (29.1) 11 (28.2) 11 (28.2)
Circular 1 (2.3) 3 (0.9) 1 (2.6) 2 (5.1)
Gross type 1.000 1.000
Borrmann I 3 (7.0) 27 (8.3) 2 (5.1) 3 (7.7)
Borrmann II 11 (25.6) 83 (25.4) 9 (23.1) 8 (20.5)
Borrmann III 24 (55.8) 178 (54.4) 23 (59.0) 22 (56.4)
Borrmann IV 5 (11.6) 39 (11.9) 5 (12.8) 6 (15.4)
Mean tumor size (mm) 60.6±32.4 44±25.2 <0.001 55.2±24.8 59.1±21.7 0.462
T classification <0.001 0.891
T2 8 (18.6) 122 (37.3) 8 (20.5) 9 (23.1)
T3 6 (14.0) 104 (31.8) 5 (12.8) 6 (15.4)
T4a 29 (67.4) 101 (30.9) 26 (66.7) 24 (61.5)
Data are shown as a mean±standard deviation or number of patients (proportion).
SPHLD = spleen-preserving hilar lymph node dissection; LN = lymph node; LC = lesser curvature; GC = greater curvature; AW = anterior wall; PW = posterior wall.
Comparison of the characteristics before and after propensity score 
matching between the D2 and the D1+ groups
To investigate the impact of D2 LND, the D2 group (n=122, splenectomy+SPHLD) was 
compared with the D1+ group (n=248) (Table 3). More advanced disease (larger tumor size 
and higher T classification) was observed in the D2 group than in the D1+ group (P=0.011 and 
P=0.011, respectively). After 1:1 propensity score matching with the same seven variables, 107 
pairs of patients with similar clinicopathological features were matched (P>0.05).
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Fig. 3. Kaplan-Meier overall and relapse-free survival curves for patients with splenectomy compared with those for patients with non-splenectomy (SPHLD+D1+) 
before and after propensity score matching. (A) Overall survival before matching (P<0.001). (B) Relapse-free survival before matching (P<0.001). (C) Overall 
survival after matching (P=0.123). (D) Relapse-free survival after matching (P=0.021). 
SPHLD = spleen-preserving hilar lymph node dissection.
Comparison of long-term outcomes between the D2 and the D1+ groups
When comparing the survival curves between the D2 and the D1+ groups before propensity 
score matching, the D2 group had worse overall and relapse-free survival than the D1+ 
group (P=0.001 and P<0.001, respectively) (Fig. 4A and B). After propensity score matching, 
comparison of the 107 matched pairs revealed similar overall and relapse-free survival 
between the 2 groups (P= 0.619 and P=0.112, respectively) (Fig. 4C and D).
Recurrence patterns
During the median follow-up period of 93.3 months, 52 of 370 patients (13, 7, and 32 patients 
in the splenectomy, SPHLD, and D1+ groups, respectively) were found to have a recurrence. 
Among them, spleen or splenic hilar LN recurrence was found in 3 (1.2%) patients. The first 
patient (54-year-old male) had T4aN0 cancer located on the lesser curvature and underwent 
D1+ LND. He experienced a recurrence in the splenic hilar and the paraaortic LNs at 36 
months after the primary operation. The second patient (64-year-old male) had T2N0 cancer 
located on the posterior wall and underwent D1+ LND. He had recurrence at the splenic 
hilar and the paraaortic LNs at 39 months after the operation. These patients were treated 
with palliative chemotherapy after diagnosis of recurrence but died within 6 and 18 months. 
The third patient (40-year-old male) underwent D1+ LND for cancer (pT3N0) located at the 
greater curvature. He had recurrence only at the splenic hilum. Splenectomy was followed, 
and 12 metastatic LNs were found among 14 dissected LNs. This patient was followed up and 
remained disease-free for more than 6 years.
Cox proportional hazard model for multivariate analysis
In a multivariate analysis to identify risk factors for overall survival using Cox proportional 
hazard model, hazard ratios (HRs) of the SPHLD group and D1+ group were 0.49 (95% 
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Table 3. Demographics of patients before and after propensity score matching between D2 dissection (splenectomy+SPHLD) and D1+ groups
Characteristics Before matching After matching
D2 (n=22) D1+ (n=248) P-value D2 (n=107) D1+ (n=107) P-value
Mean age (yr) 56.5±12.7 55.1±12.5 0.310 56.5±12.8 56.5±13.3 0.996
Sex 0.592 0.883
Male 86 (70.5) 168 (67.7) 74 (69.2) 73 (68.2)
Female 36 (29.5) 80 (32.3) 33 (30.8) 34 (31.8)
Histologic type 0.192 0.761
Differentiated 35 (28.7) 88 (35.5) 31 (29.0) 29 (27.1)
Undifferentiated 87 (71.3) 160 (64.5) 76 (71.0) 78 (72.9)
Location 0.477 0.920
LC 49 (40.2) 108 (43.5) 45 (42.1) 51 (47.7)
GC 11 (9.0) 25 (10.1) 10 (9.3) 9 (8.4)
AW 18 (14.8) 47 (19.0) 17 (15.9) 17 (15.9)
PW 42 (34.4) 66 (26.6) 34 (31.8) 29 (27.1)
Circular 2 (1.6) 2 (0.8) 1 (0.9) 1 (0.9)
Gross type 0.595 0.983
Borrmann I 13 (10.7) 17 (6.9) 11 (10.3) 12 (11.2)
Borrmann II 32 (26.2) 62 (25.0) 27 (25.2) 25 (23.4)
Borrmann III 64 (52.5) 138 (55.6) 59 (55.1) 59 (55.1)
Borrmann IV 13 (10.7) 31 (12.5) 10 (9.3) 11 (10.3)
Mean tumor size (mm) 50.9±30.3 43.5±24.3 0.011 45.9±21.6 46.6±20.9 0.822
T classification 0.011 0.962
T2 30 (24.6) 100 (40.3) 28 (26.2) 27 (25.2)
T3 41 (33.6) 69 (27.8) 36 (33.6) 35 (32.7)
T4a 51 (41.8) 79 (31.9) 43 (40.2) 45 (42.1)
Data are shown as a mean±standard deviation or number of patients (proportion).
SPHLD = spleen-preserving hilar lymph node dissection; LN = lymph node; LC = lesser curvature; GC = greater curvature; AW = anterior wall; PW = posterior wall.
confidence interval [CI], 0.26–0.91; P=0.023) and 0.41 (95% CI, 0.24–0.68; P<0.001), 
respectively, compared with those of the splenectomy group (Supplementary Fig. 1).
DISCUSSION
In this study, we found that prior to propensity score matching, patients with splenectomy 
tended to have tumors of larger size and more advanced T classification than patients 
who did not undergo splenectomy. Thus, we performed a propensity score matching to 
correct the differences in clinicopathological characteristics due to selection bias that could 
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Fig. 4. Kaplan-Meier overall and relapse-free survival curves for patients with D2 LN dissection (splenectomy+SPHLD) compared with those for patients with 
D1+ before and after propensity score matching. (A) Overall survival before matching (P=0.001). (B) Relapse-free survival before matching (P<0.001). (C) Overall 
survival after matching (P=0.619). (D) Relapse-free survival after matching (P=0.112). 
SPHLD = spleen-preserving hilar lymph node dissection.
skew oncological results. After propensity score matching, we noted no difference in the 
clinicopathological characteristics between patients who underwent splenectomy and those 
who did not. Similar results were obtained with patients who underwent D2 LND compared 
with those who underwent D1+ dissection. Survival curves after propensity score matching 
suggested that neither splenectomy nor D2 LND had a positive impact on long-term survival 
in patients with LN-negative T2-4a AGC.
The controversy surrounding the benefits of splenectomy to oncological outcomes in 
gastric cancer regardless of LN involvement has been longstanding. Previous reports have 
shown that splenectomy offers no survival benefit in the presence of metastatic LN [8,16]. 
Meanwhile, the recently published JCOG0110 trial, which compared splenectomy group with 
a non-splenectomy group for clinical AGC (cT2-4/N0-2) not invading the greater curvature, 
concluded that splenectomy was not superior to spleen preservation [17,18]. However, a 
recent report from our institution demonstrated that splenic hilar LND during splenectomy 
or with spleen preservation had a positive impact on long-term survival similar to that with 
the removal of other extra-perigastric LN groups [19]. Watanabe et al. [20] also reported from 
a single institutional data that splenectomy offers a survival benefit when cancer involves 
the greater curvature. In this study, the LN positive ratio was 68.2% in cancers involving the 
greater curvature [20]. Additionally, Ji et al. [21] recently reported that spleen-preserving 
hilar dissection elicited better survival than splenectomy for upper and middle third AGC. 
Thus, dissecting hilar LNs and preserving the spleen could be desirable in certain patients 
with proximal AGC. In the current study, we focused on patients who could be exempted 
from splenectomy or splenic hilar dissection although they had advanced diseases. Thereby, 
we were able to analyze the impacts of splenectomy and D2 LND in patients with an advanced 
disease without LN metastasis. Our results suggest that the potential hazards posed by these 
procedures may outweigh their benefits in this specific group of patients.
After the results of JCOG 0110 trial were published, there was a drive to alter the extent 
of LND in proximal AGC. Because this trial did not include tumors located in the greater 
curvature, it was considered that tumors on the other side of the proximal stomach could 
be indicated for limited LND. In this regard, Kinoshita [22] recently suggested 3 different 
procedures as follows: D2-No. 10, spleen-preserving D2, and splenectomy D2. In addition, 
according to the latest guidelines revised in 2018, splenic hilar LND is not necessary unless 
cancer involves the greater curvature of the stomach. However, in the JCOG 0110 trial, 
N0 cancer accounted for 42.2% (213/505) of all cancers. Thus, there was a possibility of 
decreased survival in the splenectomy group because of the potential adverse oncological 
impact of splenectomy on N0 cancer, although in the subgroup analysis of the study, 
contrary to our expectations, splenectomy in patients with N0 cancer tended to have a 
positive impact on the survival (HR, 1.23; 95% CI, 0.68–2.25) [17]. In this study, we tried to 
investigate whether it is possible to identify patients who do not require splenic hilar LND 
based on tumor factors, including the location. Accordingly, we suggested that patients 
with T2-4aN0M0 tumors, which are classified as stage IB–IIB based on the 7th Union for 
International Cancer Control/American Joint Committee on Cancer TNM staging system, 
could be the ideal candidates for limited LND regardless of tumor location. These patients 
in our database comprised 28.7% of the patients for whom D2 LND was indicated with a 
curative aim.
Herein, we showed the survival impact of splenectomy or D2 LND in patients with pT2-
4aN0M0 cancer involving a large amount of data using propensity score matching. 
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However, there are some limitations to this study. The critical limitation of our study is 
that we compared pathological findings. Thus, it would be difficult to apply these results 
to clinical practice, because the current preoperative diagnosis is limited to predicting pN0 
cancer. While computed tomography (CT), endoscopic ultrasound, and positron emission 
tomography-CT are used for gastric cancer staging before surgery, their sensitivity and 
specificity are not high enough to confirm nodal involvement [23]. Although Tokunaga et 
al. [24] showed that clinical findings have an effect on the survival outcomes even among 
patients with the same pathological findings, we attempted to identify the specific patient 
group which does not require splenectomy or splenic hilar LND by analyzing the pathological 
data. Nevertheless, with ongoing research, we expect that the accuracy of the preoperative 
diagnosis of N classification will improve with time, and our results could be more applicable 
for the accurate preoperative prediction of N classification. Secondly, our study was performed 
as a retrospective analysis using data from a single institution. Although the reasons for 
splenectomy were sometimes unclear, we tried to reduce selection bias by excluding T4b 
cancer and using propensity score matching. In addition, our data could be considered robust 
because these were derived from the results of a standardized treatment administered by 
experienced surgeons from a center with a high volume of patients with gastric cancer. For 
instance, although the extent of LND did not adhere to the standard treatment guidelines in 
the D1+ group, more than 40 LNs were retrieved, which was much greater than the 16 LNs 
required for proper staging (50.7, 46.6, and 42.9 in splenectomy, SPHLD, and D1+ groups, 
respectively). Furthermore, there was no accurate information on postoperative adjuvant 
chemotherapy which might have an impact on the survival. However, in general, gastric cancer 
patients in stage II or higher received our institution's standard 5-fluorouracil-based adjuvant 
chemotherapy since early 2000. Finally, even after propensity score matching, there were still 
differences in the clinicopathological characteristics and unseen bias due to latent variables, 
although we tried to reduce the bias by matching the patients for seven clinically important 
characteristics known to affect survival after treatment.
In conclusion, we found that splenectomy does not have an oncological benefit in patients 
with LN-negative AGC. In addition, we deemed D2 LND to be unnecessary for these patients. 
Although the accuracy of current preoperative nodal classification is not high enough, our 
results could play an important role in determining and revising the extent of LND for the 
treatment of proximal AGC.
SUPPLEMENTARY MATERIAL
Supplementary Fig. 1
Multivariate analysis to identify risk factors for overall survival using the Cox proportional 
hazard model.
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